Dr Wise on the Safety Profile of Pasritamig Plus Docetaxel in mCRPC

“[This was] a well-tolerated combination; we didn’t see high-grade CRS. The docetaxel toxicity was [what was expected]. There were no synergistic or worrisome toxicity signals.”

David R. Wise, MD, PhD, an associate professor in the Department of Medicine and the Department of Urology at NYU Grossman School of Medicine, discussed safety data from a phase 1b trial (NCT05818683) evaluating pasritamig in combination with docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) that were presented during the 2026 Genitourinary Cancers Symposium.

Wise noted that the adverse effect (AE) profile of pasritamig plus docetaxel was as expected based on the toxicity profiles of each individual agent. Overall, the combination was well tolerated with no high-grade cytokine release syndrome (CRS), he stated. No synergistic toxicity was reported between pasritamig and docetaxel, he added.

Specifically, no patients who received the combination (n = 51) discontinued pasritamig due to treatment-related AEs (TRAEs); 22.5% of patients discontinued docetaxel due to TRAEs. No dose-limiting toxicities, fatal TRAEs, of any-grade CRS were reported.

Most patients experienced at least 1 any-grade TRAE (98.0%). The most common any-grade TRAEs included fatigue (60.8%), alopecia (41.2%), diarrhea (31.4%), nausea (31.4%), peripheral edema (27.5%), peripheral sensory neuropathy (25.5%), dysgeusia (23.5%), and anemia (17.6%). Grade 3 or higher TRAEs occurred at a rate of 29.4% and consisted of amenia (7.8%), neutropenia (7.8%), decreased appetite (2.0%), and diarrhea (2.0%).

The most common TRAEs related to pasritamig included fatigue (33.3%), diarrhea (11.8%), and maculopapular rash (9.8%). No dose reductions of pasritamig were required.

The median duration of treatment with pasritamig was 7.39 months (range, 0.5-13.0). The median duration of treatment with docetaxel was 3.48 months (range, 0.0-11.1).

Disclosures: Wise reported holding stock and other ownership interests with Doximity; receiving Honoria from OncLive and ScientiaCME; holding consulting or advisory roles with Bayer, Janssen, K36, OncoC4, and Pfizer; and receiving travel, accommodations, and expenses from Bayer and Pfizer.